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REVIEW
Abstract: Abatacept (CTLA4-Ig) is a new agent which targets T-cell activation, an event
which is thought to be critical to the onset and maintenance of rheumatoid arthritis (RA).
Abatacept now has substantial evidence from phase III trials for efficacy in patients with RA
who have failed to respond to disease-modifying antirheumatic drugs (DMARDs) and anti-
tumor necrosis factor-alpha (TNF-α) biologic agents. Safety profile is favorable in combination
with DMARDs. The mechanism of action and available evidence of its efficacy and safety
are reviewed in this article.
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Introduction
Co-stimulation
T-cell activity depends on activation. T-cell function depends on at least two signals.
The first is provided by the binding of the T-cell receptor (TCR) to its cognate antigen.
The second is provided by one or more co-stimulatory pathways. Binding of antigen
in the absence of co-stimulation results not in activation but in anergy, a state where
the cell is refractory to stimulation. Co-stimulatory pathways have been described
for a number of cell types including memory and effector T-cells and B-Cells. Both
positive and negative co-stimulatory pathways exist.
Of these many pathways, one of the most important, which is of therapeutic interest
is that between CD80/86 on antigen-presenting cells and CD28 on naïve T-cells.
This interaction is necessary for T-cell activation. CD28 signaling mediates expression
of IL2 and anti-apoptotic molecules, amongst other effects (Jenkins et al 1991). Shortly
after activation has occurred the T-cell then expresses a number of other co-stimulatory
molecules including CTLA4, which is homologous to CD28 but binds CD80 and
CD86 with higher affinity (Linsley et al 1991). CTLA4 expression therefore results
in competitive inhibition of further binding with CD28, terminating T-cell activation.
There is evidence that CTLA4 polymorphisms are associated with loss of self-
tolerance (Gough et al 2005) and therefore that CTLA4 may help to regulate immune
responses to prevent autoimmune diseases.
Rationale for co-stimulation blockade in rheumatoid
arthritis
There is accumulating evidence that T-cells are important in the pathogenesis of
rheumatoid arthritis (RA). Transfer of T-cells from humans with RA to
immunodeficient mice can induce the clinical features of RA (Mima et al 1995). A
mouse model in which auto-reactive T-cells are selected, rather than deleted, in the
thymus results in an RA-like phenotype (Sakaguchi et al 2003). T-cell differentiation
is abnormal in RA, and abnormal T-cell phenotype correlates with disease severity
(Ponchel et al 2002).
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CD28 expression is increased in CD4+ cells from RA
patients compared with controls, and the mean expression of
CD28 is greatest for patients with clinically active disease
(Salazar-Fontana et al 2001). There is therefore a good rationale
for targeting CD28-mediated T-cell activation in RA.
CTLA4-Ig
Abatacept (CTLA4-Ig - Orencia
®, Bristol Myers Squibb,
New York, USA) is a soluble fusion protein consisting of
the extra-cellular domain of human CTLA4 and a fragment
of the Fc portion of human IgG1 (hinge and CH2 and 3
domains). It binds human B7 (CD80/86) more strongly than
CD28 (Linsley et al 1991).
Pharmacokinetics
Pharmacokinetics were studied in a phase I dose-finding
clinical trial in patients with psoriasis. Patients were
randomized to one of 8 dose levels: 0.5 mg/kg, 1 mg/kg,
2 mg/kg, 4 mg/kg, 8 mg/kg, 16 mg/kg, 25 mg/kg, and 50 mg/
kg, and within this range abatacept exhibited linear
pharmacokinetics with a mean serum half-life of 14.7 days.
There was no change in half-life throughout the dose range.
A later double-blind placebo-controlled study in RA which
tested 0.5 mg/kg, 2 mg/kg and 10 mg/kg doses found
optimum clinical response using the 10 mg/kg dose
(Moreland et al 2002).
In vitro studies have shown a dose-dependent inhibition
of T-cell proliferation by abatacept after stimulation by
antigen-presenting cells (Symington et al 1993). When
treated with abatacept 10 mg/kg on days 1, 15, 30, and then
every 30 days, minimum serum abatacept concentrations
ranged from 28.7±3.8 µg/ml on day 60 and 22.0±1.7 µg/ml
on day 180. Abatacept was able to inhibit T-cell proliferation
in vitro at concentrations between 3.16 µg/ml and 100 µg/
ml (Nadler et al 2004)
Immunological activity
Analysis of multiple biomarkers from peripheral blood of
patients in phase IIb, Abatacept in patients with an
inadequate response to methotrexate (AIM) and Abatacept
trial in treatment of anti-tumor necrosis factor inadequate
responders (ATTAIN) trials (Weisman et al 2004; Emery,
Westhovens, et al 2005) have shown reduction of a number
of biomarkers including rheumatoid factor, C-reactive
protein (CRP), soluble interleukin-2 (IL-2) receptor,
interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α),
E-Selectin, soluble intercellular adhesion molecule 1, and
matrix metalloproteinase-3 (MMP-3). These changes are
consistent with inhibition of both T-cell activation and a
downstream effect on B-Cells and antigen-presenting cells.
Abatacept causes a near-complete inhibition of T-cell
proliferation after stimulation by dendritic cells, but a
lesser inhibition when the antigen-presenting cell is a B-
Cell (Davis et al 2005). Blockade of the CD28/B7
pathway in vivo using CTLA4-Ig has also been shown
to prevent expansion of memory T-cells after re-
stimulation with antigen (Ndejembi et al 2005). No effect
of abatacept on TNF-β production by monocytes confirms
that this drug spares innate immune responses (Davis et
al 2005).
Synovial histology and gene expression have been
examined in patients treated with abatacept after failure of
anti-TNF-α therapy (Buch et al 2005). Synovial biopsies
were examined by semi-quantitative immunohistochemistry
and quantitative real-time polymerase chain reaction for
synovial messenger ribonucleic acid (mRNA) expression
at baseline and 4 months. There was a clinical response in
7/11 patients. Although there was no change in total T-cell
numbers, staining for CD4 decreased. Expression of mRNA
for interferon-γ (IFN-γ), TNF-α, MMP-1, MMP-3,
interleukin-1 (IL-1) and receptor activator of NF-κB
(RANK) decreased by 20%–50% from baseline but there
was very little change in IL-6. These findings indicate that
the mechanism of action of abatacept involves local synovial
suppression of a range of cytokines from both T-cells and
macrophages.
Immunogenicity
Since it is a fully humanized protein, and is itself
immunosuppressive, development of anti-abatacept
antibodies would not be anticipated to be a common
problem. The large scale trials on which immunogenicity
data have been published both used abatacept in combination
with methotrexate or another disease-modifying
antirheumatic drug (DMARD). In the larger, phase III trial
(Genovese, Becker, et al 2005) antibodies against abatacept
developed in 1.3% of patients and were of low reactivity.
An earlier trial (Kremer et al 2003) found no anti-abatacept
antibody seroconversion in 220 treated patients.
Efficacy
Studies of efficacy
Despite recent advances in therapies for RA there remain a
number of unmet needs for therapy (Moreland 2005). ATherapeutics and Clinical Risk Management 2006:2(4) 367
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subgroup of patients will respond to DMARD monotherapy.
In others, combinations of DMARDs or TNF-α-blockers
are needed due to resistant disease activity or toxicity. There
remain groups of patients for whom none of these treatments
are satisfactory due to toxicity or resistance. For these
reasons trials to date for abatacept have focused on: (1)
demonstrating activity against RA; (2) Demonstrating
efficacy for patients inadequately controlled by methotrexate
or TNF-α blockers; (3) demonstrating a toxicity profile that
is acceptable in general, and preferable to those of existing
therapies for some sub groups.
Outcome measures used in these studies have included
the American College of Rheumatology (ACR) response
rates, which measure the proportion of patients with a 20%,
50% or 70% improvement in number of tender and swollen
joints from 68 assessed, as well as a 20% improvement in
at least three of the following: the patient’s global
assessments of disease status, pain and physical function,
physician’s assessment of disease status, and the CRP level.
The Disease Activity Score 28 (DAS28) is another validated
measure of disease activity using similar variables of tender
and swollen joint counts from a sample of 28, erythrocyte
sedimentation rate (ESR) and patient’s assessment of global
health. The DAS28 yields a numeric value. Changes of less
than 0.6 are considered to indicate non-response, and score
of ≤2.4 with improvement of at least 1.2 a good response. A
DAS28 score of less than 2.6 indicates remission and
correlates closely with the ACR criteria for remission.
The Modified Stanford Health Assessment Questionnaire
(mHAQ) measures patient-centered outcomes of disability,
pain, and global health. It focuses on physical function
especially of the upper limb. Psychiatric and social outcomes
are not assessed. The Medical Outcome Short Form (36)
Health Survey (SF36) assesses less disease-specific
dimensions of quality of life. The scale includes physical
(physical function, limitations in role due to physical
problems, bodily pain, and general health) and mental
(vitality, social function, limitations in role due to emotional
problems and mental health) components, as well as physical
and mental summaries. Scores are in the range 0–100 for
each domain. Lower scores indicate worse function, and an
improvement of at least 3 points is considered clinically
meaningful. Physical function components of the SF36
correlate closely with the mHAQ (Talamo et al 1997).
Activity against RA has been demonstrated in a phase I
dose-ranging study (Moreland et al 2002). This study
determined the dosing schedule that has become standard
and has been used in all subsequent studies. Infusions of
abatacept are given at day 1, 15, 30 and then every 30 days
as a 30-minute intravenous infusion. The optimum dose has
been determined as 10 mg/kg. Later studies have used a
simplified dosing system using an approximation of body
weight.
Efficacy in patients who have inadequately responded
to methotrexate and other DMARDs has been assessed in a
large phase IIb trial (Kremer et al 2003; Kremer, Dougados,
et al 2005). A large phase III trial in a similar group of
patients also includes radiographic data (AIM; Emery,
Russell, et al 2005; Genant et al 2005; Kremer, Westhovens,
et al 2005; Russell et al 2005). Another phase III trial
assessed efficacy of abatacept in patients who have
inadequately responded to TNF-α-blockers, a group for
whom there are currently few therapeutic options
(Genovese, Becker, et al 2005). In addition to the safety
data available from all of these trials, there has also been a
separate large-scale study of safety in patients with a range
of co-morbidities and concomitant therapies (Abatacept
study of safety in use with other rheumatoid arthritis
therapies [ASSURE] trial) (Weinblatt et al 2005).
Studies in patients not responding to
DMARDs
Evidence for efficacy of abatacept in the group of patients
not responding to methotrexate comes from two studies,
which examine similar groups of patients. The first was a
phase IIb study of patients who had failed at least 10 mg/
week of methotrexate for at least 6 months (Kremer et al
2003; Kremer, Dougados, et al 2005). Disease activity was
high at baseline with all patients showing erosive change
and 90% positive for rheumatoid factor. Patients were treated
with either 2 mg/kg or 10 mg/kg of abatacept or placebo
according to the standard schedule. Double blind therapy
continued for 12 months and then patients in the 10 mg/kg
could enter an open label long-term extension from which
3 year data are published. Primary endpoint was ACR20 at
6 months and secondary endpoints the other ACR responses
and modified Health Assessment Questionnaire (mHAQ)
and Short-Form 36 Quality of Life Questionnaire (SF36) at
6 and 12 months. Although there was evidence of efficacy
at the 2 mg/kg dose, results were inferior to those at 10 mg/
kg with no significant difference in side-effect profile and
so later studies have used a 10 mg/kg dose only.
The second study (AIM) recruited patients who had
failed at least 15 mg/week of methotrexate for at least 3
months and randomized to either abatacept 10 mg/kg orTherapeutics and Clinical Risk Management 2006:2(4) 368
Vital and Emery
placebo. Double-blind therapy continued for 12 months.
The most important difference from the earlier phase IIb
study was that the AIM study included a radiographic
endpoint. Genant-modified Sharp Score, ACR20 and
mHAQ response were all primary endpoints. Other ACR
responses, DAS28 and SF36 at 6 and 12 months were
secondary endpoints.
Disease activity
Data from double-blind follow up of patients in both the
phase IIb and phase III AIM studies has been published in
abstract form for 6 and 12 months endpoints. These are
summarized in Figures 1 and 2. These rates of response are
high for patients who have been resistant to methotrexate,
and comparable to those achieved with anti-TNF-α agents.
A separate analysis of individual ACR components shows
improvements across all components for the phase IIb study
(see Table 1).
A separate analysis of data from the phase IIb study has
shown that improvements in disease activity, pain and
physical function occurred by 30 days (Emery et al 2004).
The proportion of patients achieving a 50% improvement
in the pain visual analog scale (VAS), mHAQ, and ACR50
were compared between treatment arms at time-points from
15 to 360 days. Visual analogue scales for disease activity
and pain were significantly better in the abatacept group by
15 days. ACR and mHAQ results are shown in Figures 3
and 4.
Some patients from the 10 mg/kg arm of the phase IIb
study entered an open-label extension for a further year.
Sustained efficacy was shown in patients who completed 2
years of treatment (Kremer et al 2004). Responses in patients
who completed follow up were sustained. These results must
be interpreted with some caution however as only 84 of the
original 115 patients randomized to abatacept 10 mg/kg
entered the extension, and of these only 74 completed 2
years of follow up. In data from the AIM trial there is a
tendency towards increasing responses between months 6
and 12, and it may be that there is cumulative improvement
in disease activity.
By post-hoc comparison of subgroups, ACR response
rates have been compared according to baseline mHAQ and
disease duration (Russell et al 2004; Kremer, Westhovens,
et al 2005). ACR response rates were independent of
baseline mHAQ and disease duration.
Structural change
The phase III AIM trial is the only study of abatacept to
include a radiographic endpoint. Since it is thought to inhibit
a number of downstream inflammatory pathways it would
be expected to indirectly reduce structural changes in a
similar fashion to DMARD and anti-TNF-α agents.
Paired radiographs at baseline and 12 months were
obtained from 92% of all randomized patients in the AIM
study. They were scored by 2 assessors, blinded for treatment
group and chronological order, using the Genant-modified
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Figure 1 ACR responses at 6 and 12 months in the phase IIb trial of abatacept versus placebo.
Abbreviations: ACR, American College of Rheumatology.Therapeutics and Clinical Risk Management 2006:2(4) 369
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Sharp Score. This includes scores for erosion and joint space
narrowing, each between 0 and 145 and a total score between
0 and 290. Median changes in these scores at 12 months
have been published in abstract form (Genant et al 2005)
and are shown in Table 2. A comparison of patients with
and without an ACR20 response was made using mean
change in Genant-modified-Sharp Score from baseline.
Although this is not usually considered the best measure
for comparing non-parametrically distributed data such as
radiographic scores, there was a significant difference
between means between abatacept and treatment groups for
ACR20 responders and non-responders for erosions, joint
space narrowing, and total scores. These data suggest that
patients whose disease activity did not respond may still
benefit from retardation of structural damage. Patients who
had an ACR response on placebo and methotrexate did not
show the same retardation of structural change as patients
on abatacept and placebo.
Function and quality of life
Results of mHAQ and SF36 have been published at 6 and
12 months for patients in the double-blind phase of the phase
IIb trial (Kremer et al 2003; Kremer, Dougados, et al 2005).
In addition, 2 and 3 year data have been published for the
84 abatacept-treated patients who entered the open-label
long term extension (Emery, Russell, et al 2005).
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Figure 2 ACR Responses at 6 and 12 months in the AIM study.
Abbreviations: AIM, Abatacept in patients with an inadequate response to methotrexate; ACR, American College of Rheumatology.
Table 1 AIM trial: improvements in measures of disease activity at 6 and 12 months
6 months 12 months
Abatacept Placebo Abatacept Placebo
(n=214) (n=424) (n=214) (n=424)
% Patients ACR20 68* 40 73* 40
ACR50 40* 17 48* 18
ACR70 20* 7 29* 6
DAS remission 14.8* 2.8 23.8* 1.9
Mean % improvement Tender joints 62.6* 40.7 68.8* 42.1
from baseline Swollen joints 65.0* 39.5 70.5* 42.4
Pain 42.5* 3.5 50.5* 8.0
Patient global VAS 42.0* 13.7 48.3* 19.6
Physician global VAS 62.2* 36.5 68.0* 37.9
CRP 24.3* -19.3 29.2* -22.7
Note: *p<0.001 versus placebo.
Abbreviations: ACR, American College of Rheumatology; AIM, Abatacept in patients with an inadequate response to methotrexate; CRP, C-reactive protein; DAS,
disease activity scores; VAS, visual analog scale.Therapeutics and Clinical Risk Management 2006:2(4) 370
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Improvement in mHAQ from baseline was already
greater in abatacept-treated patients by 30 days as previously
mentioned. This response had further increased at 6 months
(58.3% with 10 mg/kg abatacept+methotrexate (MTX) vs
33.6% with placebo+MTX, p< 0.001). At one year, by
intention to treat analysis, this appeared to have dropped
slightly (42.3% with 10 mg/kg abatacept plus MTX vs 10.3%
with placebo plus MTX, p<0.001), but the authors report
that analysis by last-observation carried forward did not
show a reduction of mHAQ between 6 and 12 months. The
sustained response in mHAQ for patients who entered the
long-term extension up to 3 years would support this. In
these patients mean percentage improvement in mHAQ from
baseline at 12, 24, and 36 months was 49.4, 46.3, and 49.3
respectively. All domains and summary scores of the SF36
had improved at 6 months for patients treated with 10 mg/
kg abatacept compared with placebo. Physical and mental
component scores have been published for the long term
extension and again in these patients these responses were
sustained.
Results for response in mHAQ, SF36 physical and
mental component summary scores, medical outcomes study
sleep module have been published for the AIM study at 6
and 12 months and are summarized in Table 3. These results
confirm that improvements in disease activity in patients
treated with abatacept translate into improvements in a
variety of patient-centred outcomes.
Studies in patients not responding to
anti-TNF-α agents
Since abatacept has a different mechanism of action, it would
be expected that patients who have failed one or more anti-
TNF-α agents may still respond to abatacept. Typically this
group of patients has few or no other therapeutic options,
as most will have failed to respond to a large number of
DMARDs already. For this reason, they also have disease
of longer duration than the other abatacept studies.
In the phase III ATTAIN trial (Genovese, Becker, et al
2005), patients had discontinued at least 3 months treatment
with anti-TNF-α agents because of lack of efficacy or still
had active disease despite anti-TNF-α, as defined by joint
counts and CRP. Patients who were unable to tolerate, or
had contraindications to, anti-TNF-α were therefore not
recruited. One stable dose background DMARD was
continued throughout the study. Concurrent therapy could
include any oral DMARD or anakinra (IL-1 receptor
antagonist), and in the majority of patients (78%) was
methotrexate. Stable low dose nonsteroidal
antiinflammatory drugs (NSAIDs) and corticosteroids were
also continued.
258 patients were randomized to abatacept and 133 to
placebo. Baseline characteristics were similar between these
two groups with high disease activity. Mean tender joint
count was greater than 30 and swollen joint count greater
than 20 for each group, with mean DAS28 of 6.5±0.9 for
the abatacept group and 6.5±0.8 for placebo.
Treatment schedules were the same as in earlier
studies using a 10 mg/kg dose. There were two primary
endpoints: the proportion of patients achieving an ACR20
response, and proportion with an improvement of ≥0.3
in mHAQ. Secondary endpoints included ACR50 and 70
response rates, improvements in DAS28, and
improvement in SF36.
Table 2 Genant-modified Sharp Score: median change from
baseline at 12 months in the AIM trial
Median change from baseline (25th, 75th
percentile)
Abatacept–MTX Placebo–MTX p (abatacept
(n=424) (n=214)  vs placebo)
Erosion score 0.00 (0.00, 1.02) 0.27 (0.00, 1.27) 0.029
Joint space 0.00 (0.00, 0.49) 0.00 (0.00, 0.97) 0.009
narrowing
Total score 0.25 (0.00, 1.78) 0.53 (0.00, 2.54) 0.012
Abbreviations: AIM, Abatacept in patients with an inadequate response to
methotrexate; MTX, methotrexate.
Table 3 Function and quality of life outcome assessments at 6
and 12 months from the AIM trial
6 months 12 months
Abatacept Placebo Abatacept Placebo
mHAQ % 35.2 20.9 37.3 19.6
improvement
mHAQ 61.1 45.3 63.7 39.3
response rate
SF36 MCS  6.2 3.8 6.9 4.7
(mean improvement
from baseline)
SF36 PCS  8.8 4.8 9.1 5.0
(mean improvement
from baseline)
MOS-sleep  −10.2 −7.8 −10.4 −6.8
(mean improvement
from baseline)
Abbreviations: AIM, Abatacept in patients with an inadequate response to
methotrexate; MCS, Short Form 36 Mental Component Summary; mHAQ,
Modified Stanford Health Assessment Questionnaire, MOS, Sleep, Medical
Outcomes Study Sleep Module; PCS, Short Form 36 Physical Component
Summary.Therapeutics and Clinical Risk Management 2006:2(4) 371
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Disease activity and function
There were significant improvements in all of the primary
and secondary endpoints at six months. Data for
improvements in the components of the ACR and DAS28
response have been published separately. These data are
summarized in Figure 5 and Table 4. These response rates
are impressive for such a resistant group of patients,
including an ACR20 rate of 50.4% and a DAS28 remission
rate of 10.0%. mHAQ improved in 47.3% of patients in the
abatacept arm compared with 23.3% on placebo. Mean
mHAQ disability index improvement from baseline was 0.45
for abatacept compared with 0.11 for placebo. Of 34
discontinuations in the placebo arm, 27 were due to lack of
efficacy and 5 due to adverse events. In the abatacept arm,
14 discontinued due to lack of efficacy and 9 due to adverse
events.
Although comparisons of efficacy between different
trials are often problematic, it is interesting to note that the
ACR response rate for highly resistant patients with longer
disease duration, who have failed both DMARDs and anti-
TNF agents, are approaching those in the phase IIb trial for
patients who have failed DMARDs only. This suggests that
the mechanism of resistance of anti-TNF is independent
from determinants of response to abatacept. This would be
consistent with the hypothesis that abatacept inhibits disease
activity in RA by mechanisms other than a downstream
effect on TNF.
Function and quality of life
It is important to confirm that improvements in disease
activity correlate with perceived health improvements in
patients with longstanding advanced RA and high baseline
mHAQ. A wide range of quality of life measures have been
reported from the ATTAIN patients including the SF36
individual and summary scores, number of days in which
Table 4 Improvements in disease activity measures at 6
months in the ATTAIN trial. ACR individual components: (Schiff
et al 2005); DAS components: (Dougados et al 2005)
Abatacept Placebo p
(n=256) (n=133)
ACR20 (% patients) 50.4 19.5 <0.001
ACR50 (% patients) 20.1 3.8 <0.001
ACR70 (% patients) 10.2 1.5 0.003
Tender Joint Count 47.8 20.0 <0.01
(mean % improvement)
Swollen Joint Count 44.3 23.8 <0.01
(mean % improvement)
Patient-reported pain 28.6 4.4 <0.001
(mean % improvement)
Patient global assessment 30.9 4.5 <0.01
(mean % improvement)
Physician global assessment 45.2 21.3 <0.01
(mean % improvement)
CRP (mean % improvement) 25.1 -28.4 <0.01
DAS Response
DAS low disease activity 17.1 3.1 <0.001
DAS Remission 10.0 0.8 <0.001
Abbreviations: ACR, American College of Rheumatology, ATTAIN, Abatacept
trial in treatment of anti-tumor necrosis factor inadequate responders; CRP, C-
reactive protein; DAS, disease activity scores.
Figure 3 Percentage of patients achieving an ACR50 response on abatacept 10 mg/kg–methotrexate or placebo–methotrexate.
Abbreviations: ACR, American College of Rheumatology.
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patients were unable to perform activities of daily living,
visual analog scales for pain and fatigue, and the medical
outcomes study sleep module. The quality of life data are
summarized in Table 5.
Subgroups of previous anti-TNF-α
therapies
Analyses of subgroups based on previous anti-TNF therapies
have also been published. Effects of anti-TNF that was
current or prior at the time of enrollment were examined.
Patients who were treated with anti-TNF-α agents at
recruitment had to have a 28–60 day washout period
(depending on type of previous therapy) before
randomization. This may have induced an artificial disease
flare that could account for the high baseline disease activity
and could potentially also lead to a high placebo response
rate. To exclude this possibility, CRP and joint counts were
compared at screening and randomization and found no
significant increase during washout. Patients were stratified
by prior or current therapy within each treatment arm. A
separate analysis compared baseline disease activity and 6
month ACR20 and mHAQ responses for the group who had
discontinued anti-TNF-α agents in the past or who were
still using anti-TNF-α before a washout (Genovese, Schiff,
et al 2005). These endpoints were met for both groups, with
small differences (ACR20 45.4% for washout and 53.3%
for prior therapy; mHAQ response 43.3% for washout and
49.4% for prior therapy). Placebo ACR response was higher
in the prior therapy group (23.1% vs 14.5%). The absence
of disease flares in the washout group excludes the
possibility that deterioration after withdrawal of anti-TNF-
α was responsible for the difference between treatment arms.
The type of anti-TNF therapy was also compared, which
in the majority of patients was etanercept, infliximab or both,
since adalimumab was not in such widespread use at the
time of enrollment. Clinical benefit was observed for all
these groups. There was a tendency towards greater
improvement for patients previously treated with infliximab
in the abatacept group but not placebo.
Safety
Safety of abatacept has been assessed by data from the
double-blind placebo controlled trials, and also a large-scale
phase III trial which had safety as its endpoint (Weinblatt et
al 2005). In view of its mode of action in suppressing T-cell
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Figure 4 Percentage of patients achieving 50% improvement in mHAQ from
baseline on abatacept 10 mg/kg–methotrexate or placebo–methotrexate.
Abbreviations: mHAQ, Modified Stanford Health Assessment Questionnaire.
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function and prior experience with other biological agents,
incidence of infection and malignancy have been the focus
of most concern in safety. Another area of concern is the
potential induction of autoimmunity. Experience with anti-
TNF-α agents has shown that there is potential for
unpredictable changes in the immune state when using
targeted therapies. Regulatory T-cells (Treg) have been shown
to have a role in preventing autoimmune disease and to have
altered function in active RA (Ehrenstein et al 2004). Since
Treg development and function is dependent on CTLA4
signaling (Tang et al 2004), another area of concern was
that CTLA4-Ig could interfere with their function and affect
tolerance to other auto-antigens. Lastly, any protein-based
biologic agent administered intravenously has the potential
to cause infusion reaction. Although this is less likely for a
fully humanized molecule, this adverse event has been
monitored closely.
In the ATTAIN trial (Genovese, Becker, et al 2005)
between the abatacept and placebo groups there were similar
rates of discontinuation due to serious adverse events and
adverse events (3.5% and 3.8%, respectively and 2.7% and
1.5%, respectively), serious adverse events (10.5% and
11.3%, respectively) and total adverse events (79.5% and
71.4%, respectively).
Although there was no increase in serious infections, or
in discontinuations due to infection, in the abatacept group,
total infection rate was increased (37.6% compared with
32.3% for placebo). These were common infections such
as nasopharyngitis and bronchitis. There was concern that
opportunistic infections similar to those seen in AIDS may
occur because of abatacept’s T-cell specific action, but this
was not substantiated. There was no report of malignancy
in the frequent (>5%) adverse events of this study.
Anti-nuclear antibodies were measured at baseline and
throughout the treatment phase. 7.5% of patients in the
abatacept group and 11.3% in the placebo group became
positive during the study. Development of anti-double-
stranded DNA antibodies was more frequent in the placebo
arm (9.4% vs 1.7% for abatacept). Clinical features of
autoimmune disease other than RA were not reported as a
frequent (>5%) adverse event.
There were no severe infusion reactions, but mild to
moderate infusion reactions were increased in patients
receiving abatacept (5.0% vs 3.0% for placebo). Headache
and dizziness were the most common symptoms.
In the phase IIb trial (Kremer et al 2003) serious adverse
events were more frequent in the placebo arm and
discontinuation rates due to adverse events were lower in
abatacept-treated patients. Most frequently reported adverse
events were similar to those in the ATTAIN study. Safety
data are not yet available from the AIM study.
Safety with other therapies and co-
morbidities
The Abatacept study of safety in use with other rheumatoid
arthritis therapies (ASSURE) was a double-blind placebo
controlled trial with safety as its endpoint. Preliminary 1-
year data have been published in abstract form (Weinblatt
et al 2005). Patients with a wide range of co-morbidities
were recruited including diabetes mellitus (7%), asthma
(6%), chronic obstructive pulmonary disease (COPD) (4%),
and congestive heart failure (1%). Treatment was with
standard dose abatacept or placebo in combination with oral
DMARDs, anti-TNF-α or anti-IL1 biologic agents. A total
of 1441 patients were randomized. The main findings are
summarized in Table 6.
The data for abatacept in combination with non-biologic
DMARD are similar to those from other trials, and are
generally reassuring. Patients with COPD experienced more
Table 5 Quality of life outcomes from the ATTAIN trial
Abatacept Placebo p
(mean change (Mean change (abatacept
from baseline) from baseline) vs placebo)
Physical function 5.3 1.3 <0.001
Physical role 6.5 1.3 <0.001
Pain 8.7 2.5 <0.001
General health 4.0 0.7 <0.001
Vitality 6.6 1.8 <0.001
Social function 7.3 2.4 <0.001
Emotional role 6.0 2.5 <0.05
Mental health 4.3 1.6 <0.01
Physical 6.6 1.1 <0.001
component
summary
Mental 5.2 2.1 <0.005
component
summary
Pain VAS -27.1 -7.9 <0.001
Fatigue VAS -21.9 -6.0 <0.001
MOS Sleep
Problems index -9.4 -2.8 <0.001
No. days unable -7.02 -1.87 <0.001
to perform activities
of daily living
Note: For SF36 characteristics values represent mean decrease from baseline. A
≥3 point decrease would be regarded as clinically meaningful. For VAS, days
unable to perform activites of daily living, and MOS Sleep problems index a
negative value indicates an improvement.
Abbreviations: ATTAIN, Abatacept trial in treatment of anti-tumor necrosis
factor inadequate responders; MOS, Sleep, Medical Outcomes Study Sleep
Module;  VAS visual analog scale.Therapeutics and Clinical Risk Management 2006:2(4) 374
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frequent exacerbations on abatacept. At the time of writing
details of rates individual infections and malignancies that
are frequently problematic in RA and immunosuppressed
patients had not been not published.
Abatacept in combination with biological agents does
not appear to be safe, with increased incidence of serious
infection and neoplasm. This combination is not
recommended.
Conclusions
There is now substantial evidence that abatacept is a safe
and effective drug for the treatment of established RA.
Its initial role is likely to be as an alternative to anti-
TNF-α agents for patients who fail to respond or have a
contraindication such as overlap with connective tissue
disease. Abatacept may however have other properties.
Since T-cells are thought to be involved in the initiation
of RA, there is a good rationale for using abatacept in
very early arthritis. It is possible that remission induced
at this stage by co-stimulation blockade could be
sustained without continuing treatment, and it will be
interesting to see results of abatacept trials in early
arthritis. In a rat model, prophylactic abatacept was found
to prevent the onset of collagen-induced arthritis
(Townsend et al 2005). Other T-cell mediated diseases
are also to be investigated. There has been recent evidence
for the use of abatacept in lupus (Davidson et al 2005)
and the use of another related co-stimulation-blocking
agent, belatacept (which also binds to CD80/86 but with
higher affinity than abatacept), in renal transplantation
(Vincenti et al 2005).
The use of abatacept in RA will become the first clinical
application of the therapeutic approach of co-stimulation
blockade that has the potential to fulfill a unique role in a
wide variety of immunological problems.
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